LEAP-015: Evaluating Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy Alone in Advanced Gastroesophageal Adenocarcinoma

Highlights

• LEAP-015 is the largest phase III trial to evaluate lenvatinib plus pembrolizumab and chemotherapy in advanced gastroesophageal adenocarcinoma.
• Combination therapy improved progression-free survival (PFS) and objective response rate (ORR) but did not significantly extend overall survival (OS).
• High rates of grade ≥3 adverse events observed with the combination regimen.
• No OS benefit in the PD-L1 CPS ≥1 subgroup, questioning the additive value of multi-modality first-line therapy.

Study Background and Disease Burden